A5071826146- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Intraperitoneal and Appendiceal Malignancies
- Wnt/β-catenin signaling in development and cancer
- Cancer-related gene regulation
- DNA Repair Mechanisms
- Cancer, Lipids, and Metabolism
- Ovarian cancer diagnosis and treatment
- Cancer-related Molecular Pathways
- Ferroptosis and cancer prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- Glycosylation and Glycoproteins Research
Caris Life Sciences (United States)
2019-2025
Phoenix (United States)
2025
Georgetown University Medical Center
2023
Georgetown University
2023
Methodist Hospital
2023
University of Kansas Medical Center
2023
IntroductionPrognosis of biliary tract cancers (BTC) remains dismal and novel treatment strategies are needed to improve survival. BRCA mutations known occur in BTC but their frequency the molecular landscape which they observed distinct sites remain unknown.Material methodsTumour samples from 1292 patients with BTC, comprising intrahepatic cholangiocarcinoma (IHC, n=746), extrahepatic (EHC, n=189) gallbladder cancer (GBC, n=353), were analysed using next-generation sequencing (NGS). Tumour...
Abstract KRAS is the most commonly mutated oncogene in NSCLC and development of direct inhibitors has renewed interest this molecular variant. Different mutations may represent a unique biologic context with different prognostic therapeutic impact. We sought to characterize genomic landscapes advanced, KRAS-mutated non–small cell lung cancer (NSCLC) large national cohort help guide future development. Molecular profiles 17,095 specimens were obtained using DNA next-generation sequencing 592...
Head and neck squamous cell carcinoma (HNSCC) is a frequently devastating cancer that affects more than half million people annually worldwide. Although some cases arise from infection with human papillomavirus (HPV), HPV-negative HNSCC common, associated worse outcome. Advanced may be treated surgery, chemoradiation, targeted therapy, or immune checkpoint inhibition (ICI). There considerable need for predictive biomarkers these treatments. Defects in DNA repair capacity loss of cell-cycle...
Abstract Pancreatic ductal adenocarcinoma (PDAC) of the head (H) and body/tail (B/T) differ in embryonic origin, cell composition, blood supply, lymphatic venous drainage, innervation. We aimed to compare molecular tumor immune microenvironment (TIME) profiles PDAC H vs. B/T. A total 3499 samples were analyzed via next-generation sequencing (NGS) RNA (whole transcriptome, NovaSeq), DNA (NextSeq, 592 genes or NovaSeq, whole exome sequencing), immunohistochemistry (Caris Life Sciences,...
Abstract Purpose: Gene fusions involving R-spondin (RSPOfp) and RNF43 mutations have been shown to drive Wnt-dependent tumor initiation in colorectal cancer. Herein, we aimed characterize the molecular features of RSPOfp/RNF43 mutated (mut) compared with wild-type (WT) cancers gain insights into potential rationales for therapeutic strategies. Experimental Design: A discovery cohort was classified status using DNA/RNA sequencing IHC. An independent used validate our findings. Results: The...
The C-C motif chemokine receptor 5 (CCR5)/C-C ligand (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated with CCR5/CCL5 expression CRC and determine whether levels could impact treatment outcomes. 7604 CRCs tested NextGen Sequencing on DNA RNA were analyzed. Molecular evaluated according CCR5 CCL5 tumor gene quartiles. outcomes was assessed two cohorts, including 6341 real-world patients 429 from Cancer Leukemia Group B...
Abstract PURPOSE Oncogenic mutations in KRAS have been identified > 85% of pancreatic ductal adenocarcinoma (PDAC) cases. G12D, G12V, and G12R are the most frequent variants. Using large clinical genomic databases, this study characterizes prognostic molecular differences between variants, focusing on G12D G12R. METHODS PDAC samples were tested using DNA RNA sequencing. MAPK activation score tumor microenvironment analyzed from expression data. Real-world overall survival (OS)...
407 Background: Intraductal carcinoma of the prostate (IDC-P) is an intra-acinar and/or intraductal neoplastic epithelial proliferation that a distinct entity in 2016 WHO classification system for cancer. Clinically, it associated with higher grade tumors and more aggressive disease course high risk local recurrence distant metastasis. However, molecular underpinnings IDC-P are not well elucidated. We present comprehensive profiling data from largest cohort cases reported to date, direct...
<div>AbstractPurpose:<p>Oncogenic mutations in <i>KRAS</i> have been identified >85% of pancreatic ductal adenocarcinoma (PDAC) cases, with G12D, G12V, and G12R being the most frequent variants. Using large clinical genomic databases, this study characterizes prognostic molecular differences between variants, focusing on <i>KRAS</i><sup>G12D</sup> <i>KRAS</i><sup>G12R</sup>.</p>Experimental Design:<p>PDAC...
RET fusions are driver alterations in cancer and most commonly found non-small cell lung well-differentiated thyroid cancer. However, fusion have been reported other solid tumors.A retrospective analysis of RET+ malignancies identified by targeted RNA sequencing whole transcriptome clinical tumor samples performed at Caris Life Science (Phoenix, AZ).As March 22, 2022, a total 378 were 15 different types carcinoma unknown primary (CUP) that underwent next-generation sequencing. NSCLC...
Abstract Polybromo-1 ( PBRM1 ) loss of function mutations are present in a fraction biliary tract cancers (BTCs). , subunit the PBAF chromatin-remodeling complex, is involved DNA damage repair. Herein, we aimed to decipher molecular landscape mutated (mut) BTCs and define potential translational aspects. Totally, 1848 BTC samples were analyzed using next-generation DNA-sequencing immunohistochemistry (Caris Life Sciences, Phoenix, AZ). siRNA-mediated knockdown was performed cell line EGI1...
Two ROS1 tyrosine kinase inhibitors have been approved for fusion positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. We performed a pan-tumor analysis of the incidence fusions to assess if more ROS1+ patients who could benefit from TKIs be identified.A retrospective solid malignancies identified by targeted RNA sequencing and whole transcriptome clinical tumor samples at Caris Life Science (Phoenix, AZ).A total 259 were approximately 175,350 tumors that underwent next-generation...
HER2 alteration (mutation and/or amplification) is associated with poor survival in NSCLC and can mediate resistance to EGFR tyrosine kinase inhibitors.We retrospectively analyzed de-identified molecular information from 12,946 samples that underwent next-generation sequencing (NGS) Caris Life Sciences. The objectives were determine the prevalence type of alterations without as a co-mutation. Insurance claims utilized obtain outcomes data.Three hundred twenty-one patients (2.5%) had...
4020 Background: KRAS is an oncogenic driver in pancreatic ductal adenocarcinoma (PDAC) with mutations identified > 90% of cases. G12D the most frequent variant, followed by G12V and G12R. We recently reported on prognostic impact distinct mutations. The current study utilized a large clinical genomic database, to further explore characterize molecular differences between variants, focusing Methods: PDAC samples were tested using whole transcriptome sequencing (WTS; Illumina NovaSeq)...
PURPOSE Using a real-world database with matched genomic-transcriptomic molecular data, we sought to characterize the distinct correlates underlying clinical differences between patients young-onset pancreatic cancer (YOPC; younger than 50 years) and average-onset (AOPC; 70 years older). METHODS We analyzed whole-transcriptome DNA sequencing data from 2,430 patient samples (YOPC, n = 292; AOPC, 2,138) Caris Life Sciences (Phoenix, AZ). Immune deconvolution was performed using quanTIseq...